Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carolyn Shembrey"'
Autor:
Lev Kats, Thomas Abrehart, Giovanna Pomilio, Carolyn Shembrey, Ricky W. Johnstone, Stephin J. Vervoort, Gareth P. Gregory, Andrew H. Wei, Izabela Todorovski, Stefan Bjelosevic, Andrea Newbold, Kristin K. Brown, Emily Gruber
Activating FMS-like tyrosine kinase 3 (FLT3) mutations occur in approximately 30% of all acute myeloid leukaemias (AMLs) and are associated with poor prognosis. The limited clinical efficacy of FLT3 inhibitor monotherapy has highlighted the need for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8113110cb44067d928c73d348301f38a
https://doi.org/10.1101/2020.05.26.116392
https://doi.org/10.1101/2020.05.26.116392
Autor:
Carolyn Shembrey, Kristin K. Brown, Izabela Todorovski, Zheng Fan, Thomas Abrehart, Giovanna Pomilio, Andrew H. Wei, Jennifer R. Devlin, Emily Gruber, Stefan Bjelosevic, Stephin J. Vervoort, Ricky W. Johnstone, Andrea Newbold, Simon J. Hogg, Lev Kats, Gareth P. Gregory
Publikováno v:
Cancer discovery. 11(6)
Internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) occurs in 30% of all acute myeloid leukemias (AML). Limited clinical efficacy of FLT3 inhibitors highlights the need for alternative therapeutic modalities in this subset o
Autor:
Gareth P. Gregory, Carolyn Shembrey, Izabela Todorovski, Ricky W. Johnstone, Thomas Abrehart, Giovanna Pomilio, Kristin K. Brown, Emily Gruber, Andrew H. Wei, Stefan Bjelosevic, Andrea Newbold, Stephin J. Vervoort
Publikováno v:
Experimental Hematology. 88:S37-S38
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all acute myeloid leukaemias (AMLs) and are associated with poor prognosis. The clinical utility of FLT3 inhibitor monotherapy has been limited by the rapid develop